ATE321860T1 - Salmonella impfstoffe - Google Patents

Salmonella impfstoffe

Info

Publication number
ATE321860T1
ATE321860T1 AT94923374T AT94923374T ATE321860T1 AT E321860 T1 ATE321860 T1 AT E321860T1 AT 94923374 T AT94923374 T AT 94923374T AT 94923374 T AT94923374 T AT 94923374T AT E321860 T1 ATE321860 T1 AT E321860T1
Authority
AT
Austria
Prior art keywords
mutation
phop
virulence
salmonella vaccines
genes
Prior art date
Application number
AT94923374T
Other languages
English (en)
Inventor
Samuel I Miller Iii
John J Mekalanos
Original Assignee
Gen Hospital Corp
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/090,526 external-priority patent/US5599537A/en
Application filed by Gen Hospital Corp, Harvard College filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE321860T1 publication Critical patent/ATE321860T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255—Salmonella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94923374T 1993-07-09 1994-07-07 Salmonella impfstoffe ATE321860T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/090,526 US5599537A (en) 1990-12-18 1993-07-09 Salmonella virulence genes
US08/271,354 US5695983A (en) 1990-12-18 1994-07-06 Salmonella vaccines

Publications (1)

Publication Number Publication Date
ATE321860T1 true ATE321860T1 (de) 2006-04-15

Family

ID=26782369

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94923374T ATE321860T1 (de) 1993-07-09 1994-07-07 Salmonella impfstoffe

Country Status (12)

Country Link
US (1) US5695983A (de)
EP (1) EP0717777B1 (de)
CN (1) CN1130923A (de)
AT (1) ATE321860T1 (de)
AU (1) AU694948B2 (de)
CA (1) CA2166787A1 (de)
DE (1) DE69434680T2 (de)
DK (1) DK0717777T3 (de)
ES (1) ES2262134T3 (de)
PT (1) PT717777E (de)
TW (1) TW493987B (de)
WO (1) WO1995002048A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843426A (en) * 1990-12-18 1998-12-01 The General Hospital Corporation Salmonella vaccines
US5599537A (en) * 1990-12-18 1997-02-04 The General Hospital Corporation Salmonella virulence genes
US6136325A (en) * 1993-04-09 2000-10-24 Lohmann Animal Health Gmbh & Co. Kg Live vaccine constituting minor risk for humans
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
ATE312934T1 (de) * 1995-06-07 2005-12-15 Univ Washington Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit
CA2237581A1 (en) * 1995-11-14 1997-05-22 The General Hospital Corporation Salmonella secreted proteins and uses thereof
US6861247B1 (en) * 1995-11-14 2005-03-01 The General Hospital Corporation Salmonella secreted proteins and uses thereof
EP0835928A1 (de) * 1996-10-11 1998-04-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Helicobacter Pylori Lebendimpfstoff
EP1012232B1 (de) 1997-09-10 2009-10-28 Vion Pharmaceuticals, Inc. Genetisch modifizierte, auf tumoren gezielte bakterien mit verminderter virulenz
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6413768B1 (en) 1998-12-02 2002-07-02 University Of Maryland Expression plasmids
US8076130B2 (en) * 1998-12-02 2011-12-13 University Of Maryland, Baltimore Plasmid maintenance system for antigen delivery
DE69935927T2 (de) 1998-12-02 2008-01-10 University Of Maryland, Baltimore Plasmidstabilisierungssystem für die verabreichung von antigenen
EP1173790A2 (de) 1999-03-01 2002-01-23 Boston Innovative Optics, Inc. Vorrichtung und verfahren zur erhöhung der tiefenschärfe des menschlichen auges
WO2001019974A2 (en) * 1999-09-10 2001-03-22 The Secretary Of State For Defence Recombinant microorganisms
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
ES2192949B1 (es) 2001-07-31 2004-08-16 Universidad De Zaragoza. Disminucion de la virulencia de mycobacterium tuberculosis por la inactivacion del gen phop.
US7195757B2 (en) * 2002-04-15 2007-03-27 Washington University Modulation of immune responses to foreign antigens expressed by recombinant attenuated bacterial vectors
US7628810B2 (en) 2003-05-28 2009-12-08 Acufocus, Inc. Mask configured to maintain nutrient transport without producing visible diffraction patterns
US20050046794A1 (en) 2003-06-17 2005-03-03 Silvestrini Thomas A. Method and apparatus for aligning a mask with the visual axis of an eye
US20100003284A1 (en) * 2003-08-29 2010-01-07 The Board Of Governors For Higher Education, State Of Phode Island And Providence Plantations Live attenuated aldolase-negative bacterial vaccine
US7976577B2 (en) 2005-04-14 2011-07-12 Acufocus, Inc. Corneal optic formed of degradation resistant polymer
US20080206758A1 (en) * 2006-10-17 2008-08-28 Lcm Technologies, Inc. Polynucleic acid-attached particles and their use in genomic analysis
EP2150616A4 (de) 2007-05-10 2011-07-27 Univ Arizona Geregelte antigensynthese und/oder geregelte attenuation zur verbesserung der impfstoff immunogenität und/oder -sicherheit
US8252897B2 (en) * 2007-06-21 2012-08-28 Angelica Therapeutics, Inc. Modified toxins
US8470314B2 (en) * 2008-02-29 2013-06-25 Angelica Therapeutics, Inc. Modified toxins
WO2010045620A1 (en) * 2008-10-17 2010-04-22 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae
ES2970433T3 (es) 2009-08-13 2024-05-28 Acufocus Inc Método de fabricación de implantes intraoculares con máscara y lentes
USD656526S1 (en) 2009-11-10 2012-03-27 Acufocus, Inc. Ocular mask
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US9545303B2 (en) 2011-12-02 2017-01-17 Acufocus, Inc. Ocular mask having selective spectral transmission
CN102676419B (zh) * 2011-12-06 2014-03-26 河南科技大学 一种伤寒沙门氏菌基因缺失菌株及由其制备的疫苗和应用
US9204962B2 (en) 2013-03-13 2015-12-08 Acufocus, Inc. In situ adjustable optical mask
US9427922B2 (en) 2013-03-14 2016-08-30 Acufocus, Inc. Process for manufacturing an intraocular lens with an embedded mask
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
CN104560855B (zh) * 2015-01-07 2018-03-02 四川农业大学 缺失phoP的鸭疫里默氏杆菌CH1减毒菌株及构建方法
CN104694432B (zh) * 2015-03-13 2018-03-09 华中农业大学 缺失phoQ和rpoS基因的都柏林沙门氏菌及应用
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN112546210A (zh) * 2020-12-15 2021-03-26 南京农业大学 一种沙门菌灭活疫苗的制备方法及应用
CN116497039B (zh) * 2022-08-30 2024-04-09 四川大学华西医院 一类phoQ基因突变体、应用及其验证方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210035A (en) * 1980-05-19 1993-05-11 Board Of Trustees Of Leland Stanford Jr. University Non-reventing live vaccines
US4837151A (en) * 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4550081A (en) * 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US5077044A (en) * 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4764370A (en) * 1984-09-12 1988-08-16 Scripps Clinic And Research Foundation Vaccine utilizing an avirulent strain of Salmonella typhimurium
ES2090129T3 (es) * 1989-03-31 1996-10-16 Univ Washington Vacunas que contienen microorganismos tipo phop avirulentos.
DE69132058D1 (de) * 1990-12-18 2000-04-20 Gen Hospital Corp Verbesserte impfstoffe
WO1992017785A1 (en) * 1991-03-29 1992-10-15 The General Hospital Corporation Detection of salmonella

Also Published As

Publication number Publication date
WO1995002048A1 (en) 1995-01-19
CN1130923A (zh) 1996-09-11
ES2262134T3 (es) 2006-11-16
DK0717777T3 (da) 2006-08-07
EP0717777A4 (de) 1998-06-10
DE69434680D1 (de) 2006-05-18
AU7325994A (en) 1995-02-06
AU694948B2 (en) 1998-08-06
TW493987B (en) 2002-07-11
EP0717777A1 (de) 1996-06-26
US5695983A (en) 1997-12-09
CA2166787A1 (en) 1995-01-19
PT717777E (pt) 2006-06-30
DE69434680T2 (de) 2007-01-04
EP0717777B1 (de) 2006-03-29

Similar Documents

Publication Publication Date Title
ATE321860T1 (de) Salmonella impfstoffe
Mobley The role of Helicobacter pylori urease in the pathogenesis of gastritis and peptic ulceration.
Kristich et al. Esp-independent biofilm formation by Enterococcus faecalis
Roe et al. Analysis of type 1 fimbriae expression in verotoxigenic Escherichia coli: a comparison between serotypes O157 and O26
DK0465560T3 (da) Vacciner indeholdende avirulente mikroorganismer af phoP-type
ATE406453T1 (de) Verfahren zür einführung und expression von genen in tierischen zellen
Salyers et al. Recent advances in Bacteroides genetics
DK0722503T3 (da) Suppressor-mutanter af mælkesyrebakterier og deres anvendelse som selektive markører og som indeslutningsmiddel i mælkesyrebakterier
BR0003943A (pt) Sequências de nucleotìdeo que codificam para o gene thre e processo para a produção enzimática de l-treonina usando bactérias corineforma
CA2097931A1 (en) Salmonella vaccines
Ryan et al. Development of a Δ glnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae
DE60029606D1 (de) Zellkulturspinnerflaschen
Brown et al. Limited boundaries for extensive horizontal gene transfer among Salmonella pathogens
Yamakawa et al. Toxin production by Clostridium difficile in a defined medium with limited amino acids
DE69925585D1 (de) Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff
Pantosti et al. Detection of intestinal and extra-intestinal strains of enterotoxigenic Bacteroides fragilis by the HT-29 cytotoxicity assay
Temprano et al. Potential use of a Yersinia ruckeri O1 auxotrophic aroA mutant as a live attenuated vaccine
YU46552B (sh) Postupak za dobijanje vakcine protiv mycoplasme
AU2001226929A1 (en) Assessment method
Halavatkar et al. The role of a 54-kb plasmid in the virulence of strains of Salmonella enteritidis of phage type 4 for chickens and mice
ATE88216T1 (de) Erhoehung der expression von genen in mikroorganismen.
Achouak et al. A major outer membrane protein of Rahnella aquatilis functions as a porin and root adhesin
KR870700096A (ko) 유용한 메탈로프로테이나제 억제제 씨퀀스 재결합 보균자계와 그의 제조를 위한 dna 재결합방법
DK361486A (da) Encellet mikroorganisme og vaccine indeholdende en saadan mikroorganisme
DeLong et al. Evolutionary relationships of superoxide dismutases and glutamine synthetases from marine species of Alteromonas, Oceanospirillum, Pseudomonas and Deleya

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0717777

Country of ref document: EP

REN Ceased due to non-payment of the annual fee